(Q39683838)

14 September 2017

title

Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors (English)

1 reference

14 September 2017

1 reference

Rajani Shakya

1

1 reference

14 September 2017

B Subba Rao

series ordinal

2

1 reference

14 September 2017

Bhawana Shrestha

series ordinal

3

1 reference

14 September 2017

language of work or name

English

0 references

publication date

30 April 2004

1 reference

Annals of Pharmacotherapy

14 September 2017

published in

1 reference

14 September 2017

volume

38

1 reference

14 September 2017

issue

6

1 reference

14 September 2017

page(s)

1074-1079

1 reference

Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status

14 September 2017

cites work

1 reference

A study of the effects of rifampicin on isoniazid metabolism in human volunteer subjects

21 January 2018

1 reference

Isoniazid-associated hepatitis deaths: a review of available information

21 January 2018

1 reference

Hepatotoxicity of antituberculosis drugs

21 January 2018

1 reference

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

21 January 2018

1 reference

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

21 January 2018

1 reference

Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.

21 January 2018

1 reference

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

21 January 2018

1 reference

Antecedent liver disease and drug toxicity

21 January 2018

1 reference

Hepatotoxicity caused by the combined action of isoniazid and rifampicin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1D525

1 reference

14 September 2017

1 reference